Carbimazole

CLINICAL USE

Treatment of hyperthyroidism

DOSE IN NORMAL RENAL FUNCTION

5–40 mg daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :186.2

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unbound (methimazole is 5%)

%Excreted unchanged in urine &nbsp &nbsp : <12 (methimazole)

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.5 (methimazole)

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :3–6.4 (methimazole)/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

arbimazole is a prodrug which is rapidly and completely metabolised to methimazole the active moiety

There have been reports of glomerulonephritis associated with the development of antineutrophil cytoplasmic antibodies in patients receiving thiourea anti-thyroid drugs.

Tags: post-by-auto-php